BR112018068135A2 - conformador aberto de hla-b57 - Google Patents
conformador aberto de hla-b57Info
- Publication number
- BR112018068135A2 BR112018068135A2 BR112018068135A BR112018068135A BR112018068135A2 BR 112018068135 A2 BR112018068135 A2 BR 112018068135A2 BR 112018068135 A BR112018068135 A BR 112018068135A BR 112018068135 A BR112018068135 A BR 112018068135A BR 112018068135 A2 BR112018068135 A2 BR 112018068135A2
- Authority
- BR
- Brazil
- Prior art keywords
- hla
- conformer
- open
- open conformer
- fusion protein
- Prior art date
Links
- 108010033369 HLA-B57 antigen Proteins 0.000 title abstract 6
- 108091006020 Fc-tagged proteins Proteins 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
a invenção refere-se a um conformador aberto de hla-b57 ou a uma proteína de fusão hla-b57 fc para uso no tratamento ou prevenção do câncer. o conformador aberto de fc compreende ou consiste em um primeiro e um segundo monômero e cada monômero compreende uma cadeia de hla-b57. a proteína de fusão fc compreende ainda uma sequência polipeptídica estabilizadora de proteína e, opcionalmente, um ligante de aminoácido. outros aspectos da invenção proporcionam medicamentos de combinação compreendendo o conformador aberto de hla-b57 fc e inibidores de ponto de verificação imunológico e/ou agentes agonistas do ponto de verificação. além disso, a invenção refere-se à utilização do conformador aberto de hla-b57 como imunomodulador, particularmente em doenças em que a modulação de diversos componentes de células imunológicas (por exemplo, células t cd8+ citotóxicas, tregs) é uma estratégia terapêutica, por exemplo, doenças infecciosas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16159099 | 2016-03-08 | ||
| PCT/EP2017/055373 WO2017153438A1 (en) | 2016-03-08 | 2017-03-07 | Hla-b57 open conformers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018068135A2 true BR112018068135A2 (pt) | 2019-01-08 |
Family
ID=55586142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018068135A BR112018068135A2 (pt) | 2016-03-08 | 2017-03-07 | conformador aberto de hla-b57 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11369660B2 (pt) |
| EP (2) | EP3795588A3 (pt) |
| JP (1) | JP6980196B2 (pt) |
| KR (1) | KR102456666B1 (pt) |
| CN (1) | CN108779164B (pt) |
| AU (2) | AU2017230855B2 (pt) |
| BR (1) | BR112018068135A2 (pt) |
| CA (1) | CA3016752A1 (pt) |
| DK (1) | DK3426681T3 (pt) |
| ES (1) | ES2828086T3 (pt) |
| MX (1) | MX2018010836A (pt) |
| WO (1) | WO2017153438A1 (pt) |
| ZA (1) | ZA201805743B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4130029A1 (en) | 2021-08-05 | 2023-02-08 | ImmunOs Therapeutics AG | Pharmaceutical compositions comprising hla fusion proteins |
| IL310615A (en) | 2021-08-05 | 2024-04-01 | Immunos Therapeutics Ag | Pharmaceutical compositions comprising HLA fusion proteins |
| EP4129323A1 (en) | 2021-08-05 | 2023-02-08 | ImmunOs Therapeutics AG | A modified hla-b57 with increased expression levels |
| CA3227617A1 (en) | 2021-08-05 | 2023-02-09 | Osiris MARROQUIN BELAUNZARAN | Combination medicaments comprising hla fusion proteins |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810099D0 (en) * | 1998-05-11 | 1998-07-08 | Isis Innovation | Novel molecule and diagnostic method |
| US7521202B2 (en) * | 1999-12-17 | 2009-04-21 | The Board Of Regents Of The University Of Oklahoma | Method and apparatus for the production of soluble MHC antigens and uses thereof |
| JP4102301B2 (ja) * | 2001-08-21 | 2008-06-18 | グラクソ グループ リミテッド | 薬剤過敏症反応についてのスクリーニング方法 |
| AU2003283963A1 (en) * | 2002-09-27 | 2004-04-19 | Ludwig Institute For Cancer Research | Mage-c2 antigenic peptides and uses thereof |
| WO2007011044A1 (ja) * | 2005-07-15 | 2007-01-25 | Kyushu University, National University Corporation | ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法 |
| CN103184291A (zh) * | 2013-04-07 | 2013-07-03 | 上海血液生物医药有限责任公司 | 一种检测人hla-b*57:01等位基因的试剂盒 |
| WO2015153969A1 (en) * | 2014-04-04 | 2015-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand discovery for t cell receptors |
| JP6792559B2 (ja) * | 2015-02-04 | 2020-11-25 | ウニヴェルズィテート チューリッヒ | 癌治療のためのｈｌａホモ二量体の使用 |
-
2017
- 2017-03-07 BR BR112018068135A patent/BR112018068135A2/pt unknown
- 2017-03-07 CA CA3016752A patent/CA3016752A1/en active Pending
- 2017-03-07 EP EP20192762.1A patent/EP3795588A3/en active Pending
- 2017-03-07 JP JP2018547384A patent/JP6980196B2/ja active Active
- 2017-03-07 CN CN201780015630.8A patent/CN108779164B/zh active Active
- 2017-03-07 US US16/083,508 patent/US11369660B2/en active Active
- 2017-03-07 WO PCT/EP2017/055373 patent/WO2017153438A1/en active Application Filing
- 2017-03-07 KR KR1020187026904A patent/KR102456666B1/ko active IP Right Grant
- 2017-03-07 ES ES17709093T patent/ES2828086T3/es active Active
- 2017-03-07 AU AU2017230855A patent/AU2017230855B2/en active Active
- 2017-03-07 DK DK17709093.3T patent/DK3426681T3/da active
- 2017-03-07 EP EP17709093.3A patent/EP3426681B1/en active Active
- 2017-03-07 MX MX2018010836A patent/MX2018010836A/es unknown
-
2018
- 2018-08-28 ZA ZA2018/05743A patent/ZA201805743B/en unknown
-
2021
- 2021-04-28 AU AU2021202634A patent/AU2021202634B2/en active Active
-
2022
- 2022-06-26 US US17/849,643 patent/US20220339250A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018010836A (es) | 2019-03-28 |
| AU2021202634A1 (en) | 2021-05-27 |
| DK3426681T3 (da) | 2020-11-16 |
| CA3016752A1 (en) | 2017-09-14 |
| US20220339250A1 (en) | 2022-10-27 |
| US11369660B2 (en) | 2022-06-28 |
| AU2017230855A1 (en) | 2018-09-27 |
| AU2021202634B2 (en) | 2022-09-15 |
| EP3795588A2 (en) | 2021-03-24 |
| ZA201805743B (en) | 2022-03-30 |
| ES2828086T3 (es) | 2021-05-25 |
| JP6980196B2 (ja) | 2021-12-15 |
| EP3426681B1 (en) | 2020-08-26 |
| EP3426681A1 (en) | 2019-01-16 |
| KR20180119605A (ko) | 2018-11-02 |
| WO2017153438A1 (en) | 2017-09-14 |
| CN108779164A (zh) | 2018-11-09 |
| EP3795588A3 (en) | 2021-05-26 |
| JP2019512231A (ja) | 2019-05-16 |
| CN108779164B (zh) | 2023-06-09 |
| AU2017230855B2 (en) | 2021-05-27 |
| KR102456666B1 (ko) | 2022-10-19 |
| US20190247466A1 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123385T1 (el) | Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης | |
| BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
| BR112018068135A2 (pt) | conformador aberto de hla-b57 | |
| CO2018002450A2 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
| PH12018500664A1 (en) | Anti-lag3 antibodies and uses thereof | |
| WO2018083087A3 (en) | Binding proteins | |
| BR112019010943A2 (pt) | métodos para o tratamento do câncer compreendendo agentes de ligação a tigit | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| BR112014021101A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo | |
| BR112015013127A2 (pt) | imunoterapia com agentes de ligação | |
| CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
| BR112017019140A2 (pt) | métodos de tratamento de câncer usando células t ativadas | |
| BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
| BR112015006828A8 (pt) | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 | |
| BR112017005736A2 (pt) | macrociclos peptidomiméticos e formulações dos mesmos | |
| BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
| CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
| BR112015020235A2 (pt) | fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit | |
| BR112015020885A2 (pt) | polipeptídeos de ligação hiperglicosilados | |
| BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
| CY1123011T1 (el) | Θεραπευτικη χρηση οστικων μορφογενετικων πρωτεϊνων | |
| BR112016000565A2 (pt) | polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |